Remdesivir, an experimental antiviral drug made by Gilead Sciences, has been authorized by the Food and Drug Administration for emergency use in treating severely ill COVID-19 patients. Ulrich Perry/POOL/AFP via Getty Images hide caption
Remdesivir, an experimental antiviral drug made by Gilead Sciences, has been authorized by the Food and Drug Administration for emergency use in treating severely ill COVID-19 patients.
Now that the Food and Drug Administration has authorized remdesivir for emergency use in seriously ill COVID-19 patients, the experimental drug is another step closer to full approval. That's when most drugs get price tags.
Gilead Sciences, which makes remdesivir, is donating its initial supply of 1.5 million doses, but the company has signaled it will need to start charging for the drug to make production sustainable. It's unclear when that decision might be made.
"Going forward, we will develop an approach that is guided by the principles of affordability and access," Gilead CEO Daniel O'Day told shareholders during the company's annual meeting Wednesday.
In a quarterly financial filing made the same day, Gilead said its investment in remdesivir this year "could be up to $1 billion or more," much of it for scaling up manufacturing capacity.
The company also acknowledged that it's in the spotlight. "[G]iven that COVID-19 has been designated as a pandemic and represents an urgent public health crisis, we are likely to face significant public attention and scrutiny about any future business models and pricing decisions with respect to remdesivir," Gilead said in the quarterly filing.
How will the company balance its business calculations with the drug's potential value to society?
"Gilead has not yet set a price for remdesivir," company spokeswoman Sonia Choi wrote in an email to NPR. "At this time, we are focused on ensuring access to remdesivir through our donation. Post-donation, we are committed to making remdesivir both accessible and affordable to governments and patients around the world."
Among potential treatments for COVID-19, remdesivir, an intravenous drug that was once studied for Ebola, is one of the furthest along.
"It's hard to imagine a situation in which there will be more public scrutiny," said Michael Carrier, a professor at Rutgers School of Law who specializes in antitrust and pharmaceuticals. "On the one hand, Gilead will try to recover its R&D in an atmosphere in which it is able to potentially make a lot of money. On the other hand, the pressure will be intense not to charge what's viewed as too high a price."
Breaking with its usual practices, the Institute for Clinical and Economic Review, or ICER, an influential nonprofit that analyzes drug pricing, issued an expedited report on remdesivir.
"Under normal circumstances, we would be unlikely to do a report when the evidence is this raw and immature," ICER President Steven Pearson said in an interview with NPR. "But it was quite clear that the world is moving at a much quicker pace."
If the price is based just on the cost of making the drug, then a 10-day course of remdesivir should cost about $10, according to the ICER report. (Gilead said results of a recently completed study suggest a five-day course of treatment may be just as effective.)
But if the drug is priced based on the drug's effectiveness, ICER estimates it should cost around $4,500 assuming the drug is proven to have some benefit on mortality. If it doesn't and the drug only shortens hospital stays, that value-based price goes down to $390.
Results from a federally funded study described by Dr. Anthony Fauci, director of the National Institute for Allergy and Infectious Diseases, suggested that remdesivir could reduce recovery time by a median of four days 11 days to recovery for patients treated with remdesivir compared with 15 days for those who got a placebo. A potential survival benefit is less clear.
Rutgers' Carrier said he expects Gilead to set the remdesivir price somewhere between the $10 and $4,500 that ICER estimated. The company has already shown that it can respond to public pressure when it asked the FDA to rescind the orphan drug status it won for remdesivir, he pointed out.
"When you see that $10 figure, that sets a benchmark for a figure that is eminently affordable," Carrier said. Ultimately, he said a price more than $1,000 per treatment course would be unpopular.
Gilead "will be watched very carefully," he said, because of its prior history of pricing. He referred to two other Gilead drugs that drew scrutiny over high price tags. The company charged $1,000 per pill for Sovaldi, a cure for hepatitis C. And its HIV drug Truvada can cost $22,000 per year.
But there is such a thing as pricing remdesivir too low, said Craig Garthwaite, who directs the health care program at Northwestern University's Kellogg School of Management.
"We don't think this is the only drug we need," he said, adding that remdesivir doesn't appear to be a "home run" against the coronavirus, based on existing data. "The thing that would worry me the most is that we're somehow telling people that if you take the risky bet to try, and you'll go after a coronavirus cure and you do it, you're not going to get paid."
Instead, he said he would like to see acceptance of a generous price for remdesivir to send the message to drug companies that the best thing they can do is "dedicate every waking moment to trying to develop that cure, and that if they do that, we will pay them the value they create," he said.
During a Gilead earnings call on April 30, analysts asked executives whether they could expect similar financial returns on remdesivir as they've seen with Gilead's other drugs.
"There is no rulebook out there, other than that we need to be very thoughtful about how we can make sure we provide access of our medicines to patients around the globe," Gilead CEO O'Day said. "And do that in a sustainable way for the company, for ... shareholders, and we acknowledge that."
On May 1, the FDA authorized remdesivir for emergency use, meaning it will be easier to administer to hospitalized patients with severe disease during the pandemic, but the drug is not yet officially approved. The federal government is coordinating distribution of the treatment.
O'Day acknowledged on the recent earnings call that the company "could" charge for remdesivir under an emergency use authorization, but he stressed that Gilead is donating its current supply, which should last through "early summer."
To date, the National Institutes of Health said it has obligated $23 million toward its COVID-19 remdesivir trial. And the U.S. Army Medical Research Institute of Infectious Diseases did some of the early in vitro and animal studies with the medicine prior to the pandemic.
"Taxpayers are often the angel investors in pharmaceutical research and development, yet this is not reflected in the prices they pay," Reps. Lloyd Doggett, D-Texas, and Rosa DeLauro, D-Conn., wrote in an April 30 letter to Health and Human Services Secretary Alex Azar.
Concerned about remdesivir's price, they asked for a full breakdown of taxpayer funds that have gone toward the development of the medicine. "An unaffordable drug is completely ineffective," they wrote in the letter. "The substantial taxpayer investments in COVID-19 pharmaceutical research must be recognized."
Read the original here:
Remdesivir Price Still A Puzzle To Be Solved By Gilead Sciences : Shots - Health News - NPR
- As 2024 Travel Hits Pre-Covid Levels, Here's When To Go To Europe - Forbes - March 10th, 2024 [March 10th, 2024]
- Comparison of Impressions of COVID-19 Vaccinations Stratified by the Number of Vaccinations Among Japanese ... - Cureus - March 10th, 2024 [March 10th, 2024]
- Effect of the COVID-19 pandemic on mental health visits in primary care: an interrupted time series analysis from nine ... - The Lancet - March 10th, 2024 [March 10th, 2024]
- Faith and rehab keep Southwick woman on path to recovery from COVID - MassLive.com - March 10th, 2024 [March 10th, 2024]
- China to draw on Covid-19 experience to tackle future pandemics - theSun - March 10th, 2024 [March 10th, 2024]
- Free COVID tests through USPS are ending todayhere's where to get tests online - Reviewed - March 10th, 2024 [March 10th, 2024]
- Concern about COVID reaches record low across political spectrum: Survey - The Hill - March 10th, 2024 [March 10th, 2024]
- He Had 217 Covid Shots Without Side Effects, Study Finds - The New York Times - March 10th, 2024 [March 10th, 2024]
- A Man Got 217 COVID-19 Vaccines. Here's What Happened - TIME - March 10th, 2024 [March 10th, 2024]
- German man vaccinated 217 times against covid with no ill effects - The Washington Post - March 10th, 2024 [March 10th, 2024]
- Andrew Cuomo Faces House Subpoena Over Covid Deaths in Nursing Homes - The New York Times - March 10th, 2024 [March 10th, 2024]
- It's been 4 years since COVID hit Michigan. For Long COVID patients, the pandemic isn't over. Michigan Advance - Michigan Advance - March 10th, 2024 [March 10th, 2024]
- 4th Anniversary of the Covid-19 Pandemic - erienewsnow.com - March 10th, 2024 [March 10th, 2024]
- Reflecting on 4 years of the COVID-19 pandemic and discussing what's to come - WBUR News - March 10th, 2024 [March 10th, 2024]
- CDC shortens 5-day COVID isolation, updates guidance on masks and testing in new 2024 recommendations - CBS News - March 10th, 2024 [March 10th, 2024]
- Father, daughter convicted in fraud related to COVID-19 relief - The Cincinnati Enquirer - February 7th, 2024 [February 7th, 2024]
- Supreme Court to weigh whether Covid misinformation is protected speech - STAT - February 7th, 2024 [February 7th, 2024]
- Oklahoma leads country in long Covid - 2 News Oklahoma KJRH Tulsa - February 7th, 2024 [February 7th, 2024]
- MCFR firefighter dies after battle with COVID-19 - WCJB - February 7th, 2024 [February 7th, 2024]
- Audio-based AI classifiers show no evidence of improved COVID-19 screening over simple symptoms checkers - Nature.com - February 7th, 2024 [February 7th, 2024]
- Hidden death toll of COVID-19 pandemic revealed - Earth.com - February 7th, 2024 [February 7th, 2024]
- Switching arms improves effectiveness of two-dose vaccinations, OHSU study suggests - OHSU News - February 7th, 2024 [February 7th, 2024]
- Tributes paid to Irish health official 'central' to EU Covid-19 response - The Irish Times - February 7th, 2024 [February 7th, 2024]
- Court: Not wearing mask during COVID-19 health emergency isn't protected speech - Honolulu Star-Advertiser - February 7th, 2024 [February 7th, 2024]
- One arm or two? How you get vaccinated may make a difference - The Seattle Times - February 7th, 2024 [February 7th, 2024]
- 70% of kindergarteners didn't pass readiness test in pandemic, study estimates - University of Minnesota Twin Cities - February 7th, 2024 [February 7th, 2024]
- USS Theodore Roosevelt sailors roam free on Guam for first time since COVID-19 outbreak - Stars and Stripes - February 7th, 2024 [February 7th, 2024]
- Pandemic linked to 14% increase in underweight children in India - Medical Xpress - February 7th, 2024 [February 7th, 2024]
- COVID and travel: Should I still wear a mask on the plane? - USA TODAY - February 7th, 2024 [February 7th, 2024]
- Vaccine hesitancy and equity: lessons learned from the past and how they affect the COVID-19 countermeasure in ... - Globalization and Health - February 7th, 2024 [February 7th, 2024]
- Increase in STIs Among Adolescents Witnessed During COVID-19 Pandemic - Drug Topics - February 7th, 2024 [February 7th, 2024]
- VDH: COVID deaths not seeing decline - Vermont Biz - February 7th, 2024 [February 7th, 2024]
- US outpatient care for serious mental health issues declined during COVID-19 - University of Minnesota Twin Cities - February 7th, 2024 [February 7th, 2024]
- COVID-19 Vaccination in a Patient With Gluten Enteropathy: A Case Report - Cureus - February 7th, 2024 [February 7th, 2024]
- COVID-19 cases drop, but still lots of flu, RSV cases in Erie County - GoErie.com - February 7th, 2024 [February 7th, 2024]
- Lives versus livelihoods: The COVID-19 trade-off from an epidemiological-economic perspective - CEPR - February 7th, 2024 [February 7th, 2024]
- Weatherhead's Jonathan Ernest notes economic changes of childcare facilities following COVID-19 pandemic - The Daily | Case Western Reserve University - February 7th, 2024 [February 7th, 2024]
- U.S. adults face distress, unequal mental health care access during the COVID-19 era - News-Medical.Net - February 7th, 2024 [February 7th, 2024]
- Simnotrelvir to reduces the symptoms of mild to moderate COVID-19 - 2 Minute Medicine - February 7th, 2024 [February 7th, 2024]
- Vaccine Effectiveness: Which COVID-19 Shots Offer the Most Protection? - SciTechDaily - February 7th, 2024 [February 7th, 2024]
- New evidence confirms COVID-19 vaccination in pregnancy is safe for babies - Gavi, the Vaccine Alliance - February 7th, 2024 [February 7th, 2024]
- Audit Committee co-chairs, Evers at odds over interest from COVID-19 funds - WisPolitics.com - February 7th, 2024 [February 7th, 2024]
- Evaluation of Olfactory Dysfunction Among COVID-19 Patients in Baghdad, Iraq - Cureus - February 7th, 2024 [February 7th, 2024]
- COVID-19's impact on early education: Retrospective study shows decrease in kindergarten readiness - News-Medical.Net - February 7th, 2024 [February 7th, 2024]
- Rutgers researchers work on breakthrough COVID-19 treatment | Video - NJ Spotlight News - February 7th, 2024 [February 7th, 2024]
- Curious Iowa: Has the state spent all of its COVID-19 relief funding? - The Gazette - October 16th, 2023 [October 16th, 2023]
- Accelerating into Immunization Agenda 2030 with momentum from ... - Infectious Diseases of Poverty - BioMed Central - October 16th, 2023 [October 16th, 2023]
- Study Uncovers Why Young Children Suffer Less Severe COVID-19 - Technology Networks - October 16th, 2023 [October 16th, 2023]
- Wenstrup, Select Subcommittee Majority Members Investigate ... - House Committee on Oversight and Reform | - October 16th, 2023 [October 16th, 2023]
- With COVID-19 emergency orders lifted, employers seek guidance ... - Hartford Business Journal - October 16th, 2023 [October 16th, 2023]
- Computer-aided diagnosis of chest X-ray for COVID-19 diagnosis in ... - Nature.com - October 16th, 2023 [October 16th, 2023]
- Maternal COVID-19 Vaccination, Infection Boosts Infant Antibody ... - Contagionlive.com - October 16th, 2023 [October 16th, 2023]
- Three Middlesex County Individuals Admit COVID-19 Fraud ... - Department of Justice - October 16th, 2023 [October 16th, 2023]
- Seventeen Broward Sheriff's Office Employees Charged with COVID ... - Department of Justice - October 16th, 2023 [October 16th, 2023]
- New COVID-19 Booster and Flu Shot Available at Select Public ... - Mecklenburg County (.gov) - October 16th, 2023 [October 16th, 2023]
- Ban on COVID vaccine mandates by private businesses, including ... - The Texas Tribune - October 16th, 2023 [October 16th, 2023]
- What Are the Side Effects of the 2023 COVID Vaccine? Experts ... - Good Housekeeping - October 16th, 2023 [October 16th, 2023]
- Covid inquiry: Bereaved families relief as High Court dismisses Cabinet Office JR - openDemocracy - July 6th, 2023 [July 6th, 2023]
- UK health agency failed to account for 3.3bn of Covid inventory, say MPs - Financial Times - July 6th, 2023 [July 6th, 2023]
- COVID-19 Working Paper: Obesity Prevalence Among U.S. Adult ... - usda.gov - July 6th, 2023 [July 6th, 2023]
- California Changes Definition of COVID-19 Outbreak Easing the ... - Fisher Phillips - July 6th, 2023 [July 6th, 2023]
- New Study Shows Robust Pandemic Preparedness Strongly Linked ... - Nuclear Threat Initiative - July 6th, 2023 [July 6th, 2023]
- COVID-19 Infection Reduces the Risk of UTIs, Bacteremia, and ... - Contagionlive.com - July 6th, 2023 [July 6th, 2023]
- Europe Phases Out COVID-19 Flexible Regulations - Pharmaceutical Technology Magazine - July 6th, 2023 [July 6th, 2023]
- Travel Pains and COVID: How to Decide if You're Ready to Travel - CreakyJoints - July 6th, 2023 [July 6th, 2023]
- COVID Depression and Anxiety | Johns Hopkins Medicine - April 17th, 2023 [April 17th, 2023]
- Man declared dead due to Covid found 'shockingly' alive after 2 years in MP - Hindustan Times - April 17th, 2023 [April 17th, 2023]
- Senate votes to end Covid-19 emergency, 3 years after initial declaration - CNN - March 31st, 2023 [March 31st, 2023]
- DC COVID-19 centers closing Friday: Here's what you need to know - WJLA - March 31st, 2023 [March 31st, 2023]
- Can grade retention help with COVID-19 learning recovery in schools? - Brookings Institution - March 28th, 2023 [March 28th, 2023]
- On 3-year anniversary of COVID-19 in NC, Winston-Salem woman shares story of loss and healing after losing 2 loved ones - WXII12 Winston-Salem - March 4th, 2023 [March 4th, 2023]
- Oregon, Washington will lift mask requirements in health care settings on April 3 - KATU - March 4th, 2023 [March 4th, 2023]
- WHO says all theories for COVID origin 'remain on table' as lab leak theory gains traction - Sky News - March 4th, 2023 [March 4th, 2023]
- New COVID-19 omicron subvariant XBB.1.5 sweeping the nation, making up majority of cases - ABC Action News Tampa Bay - February 15th, 2023 [February 15th, 2023]
- Man gets 21 years in prison for stabbing wife in the Ozarks over COVID-19 stimulus check and their children - Law & Crime - February 15th, 2023 [February 15th, 2023]
- Healthline: Medical information and health advice you can trust. - January 2nd, 2023 [January 2nd, 2023]
- China can expect repeat Covid infections with new strains on the way: experts - South China Morning Post - January 2nd, 2023 [January 2nd, 2023]
- PCR tests for travellers reintroduced around the world as Covid-19 cases surge - The National - January 2nd, 2023 [January 2nd, 2023]
- Covid-19 surge after Covid-19 surge has made it impossible for US hospitals to plan for the future - Vox.com - January 2nd, 2023 [January 2nd, 2023]
- COVID-19 in China: Demand for a particular fruit rises as people seek natural remedies to fight the virus - WION - December 21st, 2022 [December 21st, 2022]